CEOP/IVE/GDP Alternating Regimen Compared with CEOP as the First-line Therapy for Newly Diagnosed Patients with Peripheral T-cell Lymphoma: Results from a Phase 2, Multi-center, Randomized, Controlled Clinical Trial

Given the poor response to CHOP-based regimens and the potential anti-lymphoma activity by alternating chemotherapy in PTCL, we conducted a phase 2, multi-center, randomized, controlled trial, comparing the efficacy and safety of CEOP/IVE/GDP alternating regimen with CEOP in a Chinese cohort of newly diagnosed patients with PTCL.

鉴于基于CHOP方案的化疗应答不佳，且交替化疗在外周T细胞淋巴瘤（Peripheral T-cell Lymphoma, PTCL）中具备潜在抗淋巴瘤活性，本研究开展了一项Ⅱ期多中心随机对照试验，在新确诊的中国PTCL患者队列中，对比CEOP/IVE/GDP交替方案与CEOP方案的疗效与安全性。